Top

Virology Journal

Published in:

01-12-2020 | Coronavirus | Research

Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro

Authors: Cui-Cui Li, Xiao-Jia Wang

Published in: Virology Journal | Issue 1/2020

Abstract

Background

Porcine epidemic diarrhea virus (PEDV) of the family Coronaviridae has caused substantial economic losses in the swine husbandry industry. There’s currently no specific drug available for treatment of coronaviruses or PEDV.

Method

In the current study, we use coronavirus PEDV as a model to study antiviral agents. Briefly, a fusion inhibitor tHR2, recombinant lentivirus-delivered shRNAs targeted to conserved M and N sequences, homoharringtonine (HHT), and hydroxychloroquine (HCQ) were surveyed for their antiviral effects.

Results

Treatment with HCQ at 50 μM and HHT at 150 nM reduced virus titer in TCID₅₀ by 30 and 3.5 fold respectively, and the combination reduced virus titer in TCID₅₀ by 200 fold.

Conclusion

Our report demonstrates that the combination of HHT and HCQ exhibited higher antiviral activity than either HHT or HCQ exhibited. The information may contribute to the development of antiviral strategies effective in controlling PEDV infection.

Song D, Park B. Porcine epidemic diarrhoea virus: a comprehensive review of molecular epidemiology, diagnosis, and vaccines. Vírus Genes. 2012;44:167–75.PubMedPubMedCentral

Pan Y, Tian X, Li W, Zhou Q, Wang D, Bi Y, et al. Isolation and characterization of a variant porcine epidemic diarrhea virus in China. Viral J. 2012;9:195.CrossRef

Sun RQ, Cai RJ, Chen YQ, Liang PS, Chen DK, Song CX. Outbreak of porcine epidemic diarrhea in suckling piglets, China. Emerg Infect Dis. 2012;18:161–3.CrossRef

Shi D, Shi H, Sun D, Chen J, Zhang X, Wang X, et al. Nucleocapsid interacts with NP, and protects it from proteolytic cleavage, enhancing cell survival, and is involved in PEDV growth. Sci Rep. 2017;7:39700.CrossRef

Fan J, Li Y. Cloning and sequence analysis of the M gene of porcine epidemic diarrhea virus Ljb/03. Virus Genes. 2005;30(1):69–73.CrossRef

Ma Y, Chan CY, He ML. RNA interference and antiviral therapy. World J Gastroenterol. 2007;13:5169–79.CrossRef

Travella S, Keller B. Down-regulation of gene expression by RNA- induced gene silencing. Methods Mol Biol. 2009;478:185–99.CrossRef

Li CC, Dong HJ, Wang P, Meng W, Han SJ, Ning S, et al. Cellular protein GLTSCR2: a valuable target for the development of broad-spectrum antivirals. Antivir Res. 2017;142(6):1–11.CrossRef

Zhou J, Huang F, Hua X, Cui L, Zhang W, Shen Y, et al. Inhibition of porcine transmissible gastroenteritis virus (TGEV) replication in mini-pigs by shRNA. Virus Res. 2010;149(1):51–5.CrossRef

10.

Wu CJ, Huang HW, Liu CY, Hong CF, Chan YL. Inhibition of SARS-CoV replication by siRNA. Antiviral Res. 2005;65(1):45–8.CrossRef

11.

Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem. 2001;70:777–810.CrossRef

12.

Eggink D, Langedijk JP, Bonvin AM, Deng Y, Lu M, Berkhout B, et al. Detailed mechanistic insights into HIV-1 sensitivity to three generations fusion inhibitors. J Biol Chem. 2009;284:26941–50.CrossRef

13.

Nishikawa H, Nakamura S, Kodama E, Ito S, Kajiwara K, Izumi K, et al. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int J Biochem Cell Biol. 2009;4:891–9.CrossRef

14.

Pan C, Liu S, Jiang S. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. J Formos Med Assoc. 2010;109:94–105.CrossRef

15.

Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77:8801–11.CrossRef

16.

Gao J, Lu G, Qi J, Wu Y, Deng Y, Geng H, et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol. 2013;87(24):13134–40.CrossRef

17.

Wang XJ, Li CG, Chi XJ, Wang M. Characterisation and evaluation of antiviral recombinant peptides based on the heptad repeat regions of NDV and IBV fusion glycoproteins. Virology. 2011;416:65–74.CrossRef

18.

Li CG, Tang W, Chi XJ, Dong ZM, Wang XX, Wang XJ. Cholesterol tag at N-terminal of the relatively broad spectrum of fusion inhibitory-peptide targets earlier stage of fusion glycoprotein activation and increases peptide’s antiviral potency in vivo. J Virol. 2013;87:9223–32.CrossRef

19.

Zhou H, Xu RZ, Gu Y, Shi PF, Qian S. Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia. Leuk Lymphoma. 2018;15:1–13.

20.

Dong HJ, Wang ZH, Meng W, Li CC, Hu YX, Zhou L, et al. The natural compound homoharringtonine presents broad antiviral activity in vitro and in vivo. Viruses. 2018;10(11):601.CrossRef

21.

Guo X, Zhang M, Zhang X, Tan X, Guo H, Zeng W, et al. Porcine epidemic diarrhea virus induces autophagy to benefit its replication. Viruses. 2017;9(3):53.CrossRef

22.

Tang TT, Lv LL, Pan MM, Wen Y, Wang B, Li ZL, et al. Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. Cell Death Dis. 2018;9(3):351.CrossRef

23.

Wang LF, Lin YS, Huang NC, Yu CY, Tsai WL, Chen JJ, et al. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2015;35(3):143–56.CrossRef

24.

Kumar A, Liang B, Aarthy M, Singh SK, Garg N, Mysorekar I, et al. Hydroxychloroquine inhibits Zika virus NS2B-NS3 protease. ACS Omega. 2018;3(12):18132–41.CrossRef

25.

Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326:905–8.CrossRef

26.

Stein EA, Pinkert S, Becher PM, Geisler A, Zeichhardt H, Klopfleisch R, et al. Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice. J Infect Dis. 2015;211(4):613–22.CrossRef

27.

Branche E, Tang WW, Viramontes KM, Young MP, Sheets N, Joo Y, et al. Synergism between the tyrosine kinase inhibitor sunitinib and anti-TNF antibody protects against lethal dengue infection. Antivir Res. 2018;158(10):1–10.CrossRef

28.

Boutimah F, Eekels JJ, Liu YP, Berkhout B. Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors. Antivir Res. 2013;98:121–9.CrossRef

29.

Sheridan MH. Patisiran: First Global Approval. Drug. 2018;78(15):1625–31.CrossRef

30.

Ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther. 2006;14:883–92.CrossRef

31.

Hinton TM, Doran TJ. Inhibition of chicken anaemia virus replication using multiple short-hairpin RNAs. Antivir Res. 2008;80:143–9.CrossRef

32.

Jain B, Jain A. Taming influenza virus: role of antisense technology. Curr Mol Med. 2015;15:433–45.CrossRef

33.

Xu YF, Shen HY, Zhao MQ, Chen LJ, Li YG, Liao M, et al. Adenovirus-vectored shRNAs targeted to the highly conserved regions of VP1 and 2B in tandem inhibits replication of foot-and-mouth disease virus both in vitro and in vivo. J Virol Methods. 2012;181(1):51–8.CrossRef

34.

Achazi K, Patel P, Paliwal R, Radonić A, Niedrig M, Donoso-Mantke O. RNA interference inhibits replication of tick-borne encephalitis virus in vitro. Antivir Res. 2012;93(1):94–100.CrossRef

35.

Shen H, Zhang C, Guo P, Liu Z, Zhang J. Effective inhibition of porcine epidemic diarrhea virus by RNA interference in vitro. Virus Genes. 2015;51(2):252–9.CrossRef

36.

Wang Z, Ren L, Zhao X, et al. Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J Virol. 2004;78:7523.CrossRef

37.

Zhao P, Wang B, Ji CM, Cong X, Wang M, Huang YW. Identification of a peptide derived from the heptad repeat 2 region of the porcine epidemic diarrhea virus (PEDV) spike glycoprotein that is capable of suppressing PEDV entry and inducing neutralizing antibodies. Antivir Res. 2017;150:1–8.CrossRef

38.

Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today. 2013;18(17–18):807.CrossRef

Title: Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro
Authors: Cui-Cui Li
Xiao-Jia Wang
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Coronavirus
Hydroxychloroquine
Published in: Virology Journal / Issue 1/2020
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-020-01342-w

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro

Abstract

Background

Method

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

The recombinant pseudorabies virus expressing African swine fever virus CD2v protein is safe and effective in mice

Association of genotype III of dengue virus serotype 3 with disease outbreak in Eastern Sudan, 2019

Viral metagenomics revealed diverse CRESS-DNA virus genomes in faeces of forest musk deer

Hepatitis E virus infection during pregnancy

Isobavachalcone inhibits Pseudorabies virus by impairing virus-induced cell-to-cell fusion

Longitudinal transcriptomic characterization of viral genes in HSV-1 infected tree shrew trigeminal ganglia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page